Method of producing aromatic thiol derivatives during hydrogenation of disulphides

FIELD: chemistry.

SUBSTANCE: invention relates to methods of producing thiophenols during reaction of corresponding disulphide with hydrogen in presence of a heterogeneous hydrogenation catalyst based on a transition metal. In particular, method of producing a compound of formula (I') involves reaction of a compound of formula (II'), wherein R is H or with H2 in presence of a heterogeneous hydrogenation catalyst based on a transition metal, where heterogeneous hydrogenation catalyst based on a transition metal is a Raney catalyst, Pd/C, Pd(OH)2/C, nanoparticles of palladium (0), micro-encapsulated in a polyurea matrix, Au/TiO2, Rh/C, Ru/Al2O3, Ir/CaCO3, Pt/C or mixture thereof. When reaction is carried out in presence of an acylating reagent, such as anhydride or halide of carboxylic acid, acylated thiophenol is obtained.

EFFECT: pharmaceutically active compound S-[2-[1-(2-ethylbutyl)cyclohexylcarbonylamino]-phenyl]-2-methylthiopropionate is obtained during said method.

20 cl, 16 ex, 1 tbl

 



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to novel compounds of formula III or to its pharmaceutically acceptable salts, in which: R1 and R2 are independently selected from group, consisting of: (a) H, (b) (C2-C6)alkyl, (c) C1-C6 alkyl, interrupted by one or more groups -O-, (d) (C0-C3)alkyl-(C3-C7)cycloalkyl and (e) (CH2)nQ, where n=1-2 and where Q stands for aromatic ring system, which has from 5 to 6 ring atoms C, and Q can be independently substituted with groups up to 3 in number, selected from halogen, on condition that R1 and R2 simultaneously do not stand for H, and each alkyl of R1 and R2 can be independently substituted with one or more groups, selected from group, consisting of halogen, hydroxy, cyano, CF3 or C1-C4 alkyl, or R1 and R2 together with carbon, to which they are attached, form 3-7-member cycloalkyl or 6-member heterocycloalkyl ring, including one oxygen atom and which in case of necessity carries C1-C4 alkyl substituent, or R1 and R2 together with carbon, to which they are connected, form 3-7-member cycloalkyl ring, substituted with R20 and R21, and R20 and R21 together with carbon or carbons, to which they are connected, form 3-7-member cycloalkyl ring; R6 stands for C1-C6 alkyl; each R7 independently stands for C1-C6 alkyl; Y stands for -O-; R4 is selected from group, consisting of: (a) (C0-C3)alkyl-(C3-C7)cycloalkyl, (b) trifluoroethyl, and (c) trifluoropropyl; Z stands for phenyl or bicyclic ring system, which has 9 ring atoms, independently selected from C, N, O and S, on condition that not more than 3 ring atoms in any single ring differs from C, and said ring system can carry to 3 substituents, independently selected from group, consisting of R6, CF3 and SR6; and R5 is selected from group, consisting of NO2, NH2, F, Cl, Br, CN, SR6, S(O)2N(R7)2 and (C1-C4)alkyl, and each alkyl can be independently substituted with one or more halogens or CF3. Invention also relates to pharmaceutical composition for treatment of neurodegenerative disorder or improvement of cognitive function, containing therapeutically effective quantity of said compound; as well as to method of treatment of neurodegenerative disorder, for instance Alzheimer's disease, or improvement of cognitive function.

EFFECT: compounds act as modulators of gamma-secretase.

31 cl, 14 tbl, 3147 ex, 1 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of general formula (I) , where is a substituted 5-member heteroaryl ring selected from thienyl, thiazolyl, oxazolyl, pyrrolyl, imidazolyl or pyrazolyl, W is selected from a group comprising N and -C=; M is selected from a group comprising -C(O)N(R1)OR2, -CXCONR1R2 and -C(O)OR1, or M is -C1-C2alkyl-C(O)N(R1)OR2, wherein is , R1 and R2 are independently selected from a group comprising -H, C1-C3-alkyl, C6-aryl, and C1-C3-alkyl-C6-aryl; R is selected from a group comprising H, C1-C3alkyl, halogen, NR1R2, -OR1 and C6aryl; n is an integer from 0 to 1; L and Y are as indicated in the claim; and to compounds of formula (II) , where L2 is selected from a group comprising H, - C0-C3alkyl- C6aryl, -C0-C3alkyl-heteroaryl, where the heteroaryl is pyridyl; -C1-C6alkyl, Y and M are the same as for compounds of formula (I). The invention also relates to a pharmaceutical composition based on compounds (I) and (II), having inhibiting action on histone deacetylase (HDAC), a method of inhibiting and a method of treating a disease which is sensitive to the HDAC inhibitor.

EFFECT: compounds of formula I and II as histone deacetylase inhibitors.

18 cl, 18 dwg, 10 tbl, 19 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula

,

where R denotes a substituted or unsubstituted thiazolyl group of formula or ; R4 and R5, each independently, are selected from i) hydrogen; ii) a substituted or unsubstituted C1-C6 linear, C3-C6 branched or C3-C6 cyclic alkyl; iii) a substituted or unsubstituted phenyl; iv) a substituted or unsubstituted heteroaryl containing 5 or 6 ring atoms and 1 or 2 heteratoms, where the heteroatoms are selected from nitrogen, oxygen, sulphur and combination thereof; or R4 and R5 can be taken together to form a saturated or unsaturated ring, having 5-7 atoms; said substitutes are independently selected from one or more groups, selected from C1-C6 linear, C3-C6 branched or C3-C6 cyclic alkyl, halogen, hydroxyl or cyano; R6 denotes a group selected from i) hydrogen; ii) a substituted or unsubstituted C1-C6 linear, C3-C6 branched or C3-C6 cyclic alkyl; iii) a substituted or unsubstituted phenyl or iv) a substituted or unsubstituted heteroaryl containing 5 or 6 ring atoms and 1 or 2 heteroatoms, where the heteroatoms are selected from nitrogen, oxygen, sulphur and combination thereof; where said substitutes are independently selected from one or more groups selected from C1-C6 linear, C3-C6 branched or C3-C6 cyclic alkyl, halogen, hydroxyl or cyano; R1 is selected from i) hydrogen; ii) C1-C6 linear or C3-C6 branched alkyl; iii) a substituted or unsubstituted phenyl or iv) a substituted or unsubstituted benzyl; where said substitutes are independently selected from one or more groups selected from C1-C6 linear, C3-C6 branched or C3-C6 cyclic alkyl, halogen, hydroxyl or cyano; R2 is selected from i) C1-C6 linear or C3-C6 branched alkyl or ii) C1-C6 linear or C3-C6 branched alkoxy; R3 denotes hydrogen or C1-C4 linear or C3-C6 branched alkyl.

EFFECT: compounds of formula (I) are effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors.

20 cl, 10 tbl, 8 ex

FIELD: chemistry.

SUBSTANCE: disclosed compounds can be used as a medicinal agent having CXCR2 inhibiting properties. In formula I , X denotes -CR3=CR4-, -CR5=N-, -N=CR6-, -NR7- or -S-; R3, R4, R5 and R6 independently denote hydrogen, F, CI, Br, I; R7 denotes hydrogen; Y1, Y2, Y3 and Y4 independently denote -CR8- or nitrogen, provided that at least two of Y1, Y2, Y3 and Y4 denote -CR8-; where R8 denotes hydrogen, F, CI, Br, I; A denotes a cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms; a bicyclic partially saturated 9-member cycloalkyl; a bicyclic partially saturated 9-10-member heterocycle in which two atoms in the ring are oxygen atoms; phenyl; naphthyl; a 5-6-member heteroaryl in which 1-3 atoms in the ring are oxygen, sulphur and nitrogen atoms; a 9-10-member bicyclic heteroaryl in which 1-3 atoms in the ring are nitrogen, oxygen and sulphur atoms; a 6-member heterocycle in which one atom in the ring is a nitrogen atom and which can be unsubstituted or substituted with alkyl having 1, 2, 3 or 4 carbon atoms, -C(O)CH3, -C(O)CH2CH3, -C(O)cyclopropyl, -C(O)CF3 and -C(O)OC(CH3)3; where phenyl, heterocyclic or heteroaryl radical is substituted with 1, 2 or 3 radicals selected from a group consisting of F, O, Br, I, OH, CN, NO2, SCF3, SF3, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, where 1, 2, 3 hydrogen atoms may be substituted with fluorine atoms; cycloalkyl having 3, 4, 5 or 6 carbon atoms; alkoxy having 1, 2, 3, 4, 5 or 6 carbon atoms, where 1, 2, 3 hydrogen atoms may be substituted with fluorine atoms; -S-alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, where 1, 2, 3 hydrogen atoms may be substituted with fluorine atoms; -NR9R10, C(O)R44, S(O)SR47, -(CH2)k-phenyl, 5-6-member heteroaryl, in which 1-3 atoms in the ring are nitrogen and sulphur atoms; where the phenyl radical may be substituted with F, CI, Br, I; R9 is an alkyl having 1, 2, 3 or 4 carbon atoms; R10 is an alkyl having 1, 2, 3 or 4 carbon atoms; R44 is an alkyl having 1, 2, 3 or 4 carbon atoms, where 1, 2, 3 hydrogen atoms may be substituted with fluorine atoms; alkoxy having 1, 2, 3 or 4 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms; R47 is an alkyl having 1, 2, 3 or 4 carbon atoms; k equals 0, 1, 2 or 3; s equals 1 or 2; B is -O-C(R11R12), -C≡C-, -CR52=CR53-, -C(R13R14)C(R15R16), -NR17-C(R18R19); R11, R12, R13, R14, R15, R16, R17, R18, R19, R52, R53 independently denote hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; D is C(O)OH, C(O)NHR21 or C(=NR58)NHR22; R21 and R22 independently denote hydrogen, -SO2-alkyl having 1, 2, 3 or 4 carbon atoms, -SO2-phenyl; R58 is OH; R1 and R2 independently denote an alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, where the alkyl radicals are unsubstituted or substituted with 1 radical selected from a group consisting of F, Cl, Br, I, phenyl substituted with OH; or R1 and R2, taken together with a carbon atom with which they are bonded form a 3-, 4-, 5- or 6-member carbocycle. The invention also relates to use of formula I compounds in preparing a medicinal agent which has CXCR2 inhibiting properties, to a medicinal agent which containing an effective amount of the disclosed compound and having CXCR2 inhibiting properties, as well as to use of formula II compounds (formula and values of radicals are given in the formula of invention) in preparing a medicinal agent having CXCR2 inhibiting properties.

EFFECT: high effectiveness of application.

10 cl, 384 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of general formula

, where R1 is a

or or or group, R2 is morpholine or OR' or N(R")2; R' is a lower alkyl, a lower alkyl substituted with a halogen, or -(CH2)n-cycloalkyl; R" is a lower alkyl; R is NO2 or SO2R'; R4 is hydrogen, hydroxy, halogen, NO2, lower alkoxy, SO2R' or C(O)OR"; R5/R6/R7 denote hydrogen, halogen, lower alkyl; X'/X1 denote CH or N, provided that X1 /X1' are not CH at the same time; X2 is O or S; n equals 0 or 1, and to their pharmaceutically active acid-addition salts. The invention also relates to a drug.

EFFECT: obtaining novel biologically active compounds which are active as glycine transporter 1 inhibitors.

11 cl, 24 ex, 1 tbl

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to compounds of the general formula (I): wherein A means benzene ring optionally substituted with one or more the following groups: -OR2 wherein R2 mean linear or branched (C1-C5)-alkyl; X means -CH=, -CH2-, -N= or -NH-radical; Y means radical -CH2, oxygen or sulfur atom or group -NR7 wherein R7 means hydrogen atom or linear or branched (C1-C5)-alkyl; R1 means hydrogen atom, linear or branched (C1-C5)-alkyl, and to pharmaceutically acceptable salts also. Also, invention relates to a pharmaceutical composition showing anti-diabetic activity. The pharmaceutical composition comprises compound of the general formula (I) as an active component and an inert excipient. Invention provides bicyclic derivatives of guanidine eliciting anti-diabetic activity.

EFFECT: valuable medicinal properties of compounds and composition.

8 cl, 2 tbl, 4 ex

FIELD: organic chemistry, chemical technology.

SUBSTANCE: invention relates to a method for preparing a substituted alkylamine derivative from the 2-aminothiophenol compound with high industrial yield that can be used as an intermediate compound used in medicine or in agriculture. Invention proposes a method for preparing substituted alkylamine derivative represented by the following general formula (3): wherein X mean halogen atom, alkyl group, alkoxy-group, cyano-group or nitro-group; n means a whole number from 1 to 4; each R1 and R2 means independently hydrogen atom of phenyl-substituted, or unsubstituted alkyl group that can in common form 5- or 6-membered cycle, or its additive acid salt. Method involves addition of 2-aminothiophenol derivative salt represented by the following formula (1): wherein X and n have abovementioned values to acid to provide pH value 6 or less and to convert salt to free 2-aminothiophenol derivative of the general formula (1) followed by addition of 2-aminothiophenol derivative with amino-N-carboxyanhydride to the reaction represented by the following general formula (2): wherein each R1 and R2 have abovementioned values. Invention provides the development of a method for unimpeded preparing 1-(2-benzothiazolyl)-alkylamine derivative, i. e. substituted alkylamine derivative from the 2-aminothiophenol derivative with the satisfactory industrial yield and without pollution of the environment.

EFFECT: improved preparing method, valuable properties of compound.

8 cl, 13 ex

FIELD: organic chemistry, chemical technology.

SUBSTANCE: invention relates to a method for preparing amido acid ester that is useful as an intermediate substance in synthesis of agrochemical preparation. Invention relates to amido acid ester represented by compound of the general formula (7): wherein A represents substituted or free lower alkylene group, and so on; R1 represents substituted or free lower alkyl group, and so on; R3 represents hydrogen atom or lower alkyl group. Method for preparing amido acid ester involves interaction of amino acid represented by compound of the general formula (1): in presence of water with halogenated carboxylic acid ester represented by compound of the general formula (2): wherein X represents halogen atom with formation of amide represented by compound of the formula (3): Then amide compound interacts with halogenated carboxylic acid ester represented by compound of the general formula (4): wherein R2 represents substituted or free lower alkyl group, and so on; X represents halogen atom with preparing carboxylic acid mixed anhydride represented by compound of the general formula (5): Then carboxylic acid mixed anhydride interacts with amine compound represented by compound of the general formula (6): A, R1 and R3 have the same values as given above; Het represents substituted of free heterocyclic group. Invention provides reducing economic indices of the process.

EFFECT: improved preparing method.

9 cl, 2 ex

The invention relates to new derivatives of asola General formula I, where R1and R2the same or different, each represents hydrogen, cycloalkyl and so forth, or R1and R2forming (a) a condensed ring, (b) or (C), which may be optionally substituted substituted lower alkyl, amino group and the like; R3, R6, R7, R8the same or different, each represents a hydrogen atom, and so on; R4represents a cyano, tetrazolyl, -COOR9and so on; R5represents a hydrogen atom or lower alkyl; D represents optionally substituted lower alkylene; X and Z are the same or different, each represents oxygen or sulfur, Y is-N= or-CH=; A is-B is-O-, -S-B-, -B-S - or-In-; represents the lowest alkylene or lower albaniles; n = 2

The invention relates to a method for producing derivatives of General formula (I), which allows to improve the yield of these products

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a method for preparing S-[2-[1-(2-ethylbutyl)cyclohexylcarbonylamino]-phenyl]-2-methylthiopropionate of the formula (I), which is applicable as a pharmaceutically active compound. The method involves a reaction of the compound of the formula (II) and isobutyric anhydride and a reducing agent.

EFFECT: method enables preparing high-yield S-[2-[1-(2-ethylbutyl)cyclohexylcarbonylamino]-phenyl]-2-methylthiopropionate.

10 cl, 12 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula I

or a pharmaceutically acceptable salt thereof, where R1 is H or R1 and R2 together with a nitrogen group can form where A, B, C and D are independently selected from a group consisting of CR1a and N; where at least one of A, B, C and D is CR1a; where R1a is selected from a group consisting of H, -ORi, -SRii, -S(O)Riii, -C(O)NRvRvi and CF3, where Ri is selected from a group consisting of methyl, ethyl, propyl, hydroxyethyl, hydroxypropyl, 2-oxo-2-phenylethyl, butyl, acetonitrile and benzyl; Rii, Riii and Riv denote methyl; Rv and Rvi are independently selected from a group consisting of H, methyl, ethyl, hydroxyethyl, hydroxypropyl, diethyalminoethyl, phenyl, pyridinyl, methoxyethyl, hydroxyethoxyethyl, benzyl, phenylethyl, 2-hydroxy-1-hydroxymethyl-2-phenylethyl and carbomoylethyl, or Rv and RVi together form morpholine or ethyl ester of piperazine; R2 is selected from a group consisting of phenyl, naphthyl, pyrazolyl and C1-C8alkylene phenyl; R3 is C1-C8alkylene; R4 is selected from a group consisting of H, C1-C8alkyl and -C=NH(NH2). The invention also relates to compounds of formulae I-A

I-B I-C

I-D I-E

values of radicals of which are given in the claim; a method of treating said pathological conditions, a pharmaceutical composition based on said compounds, a method of identifying a Trp-p8 agonist and specific compounds.

EFFECT: obtaining compounds which are useful as Trp-p8 modulators.

25 cl, 19 dwg, 8 tbl, 17 ex

The invention relates to an inhibitor of the activity of esterified cholesterol transport protein (HETB), comprising as active ingredient a compound represented by the formula (I), where R is a straight or branched alkyl group; a lower halogenating group; substituted or unsubstituted cycloalkyl group; substituted or unsubstituted cycloalkylcarbonyl group; substituted or unsubstituted aryl group, or substituted or unsubstituted heterocyclic group, X1X2X3and X4may be the same or different and each represents a hydrogen atom, halogen atom, lower alkyl group, lower halogenating group; a lower alkoxygroup; a cyano; a nitro-group; Y represents-CO -, and Z represents a hydrogen atom or mercaptohexanol group, or its pharmaceutically acceptable salt, or hydrate, or MES

FIELD: chemistry.

SUBSTANCE: invention relates to method of continuous obtaining methylmercaptane by interaction of initial mixture, which contains dialkyl sulphides and dialkyl polysulphides, with hydrogen sulphide. Process is carried out in presence of catalyst based on Al2O3, SiO2, TiO2, alumosilicates, zeolites, bentonites or alumina, containing, at least, 1 wt % of alkali metal oxide, or catalyst, consisting of said compounds, in reactor with, at least, two separate catalyst-containing zones or in several successively placed reactors, and prevailing part or entire amount of said dialkyl sulphides and/or dialkyl polysulphides together with, at least, part of entire amount of used hydrogen sulphide is supplied into first catalyst-containing zone of reactor, and the remaining amount of hydrogen sulphide and dialkyl sulphides and/or dialkyl polysulphides is dosed into space between catalyst-containing zones, and initial gas mixture can also contain dialkyl ethers, which react with hydrogen sulphide with formation of alkylmercaptanes.

EFFECT: novel method of obtaining alkylmercaptanes with high selectivity is elaborated.

13 cl, 3 dwg, 2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to an improved method of producing a carbonate compound, involving reaction of a compound of formula , wherein each of X1-X6 represents a chlorine atom, with a compound having one OH group, or a compound having two or more OH groups, in the presence of a catalyst, the catalyst containing a halogen salt.

EFFECT: invention is meant for selective production of various types of carbonate compounds without any inhibition of high output, without using phosgene and without obtaining hydrogen chloride as a by-product.

12 cl, 18 tbl, 18 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to improved methods for preparing a hydrazide product of hydrazine and acid chlorides, particularly to a method for preparing 3-methyl-3-mercaptobutanoic acid hydrazide. The method involves the stages as follows: (a) preparing a stirred, substantially uniform suspension containing hydrazine and an inert solvent, and (b) continuously adding acid chloride to said suspension, wherein acid chloride has the structure: , wherein P represents a thiol-protective group; each of R1 and R2 are specified in a group consisting of C1-C5 alkyl; L represents an alkylene linker with continuously adding of the acid chloride solution adjusted so that a reaction temperature maintained within the range of -65°C to -75°C. The invention also refers to a method for preparing a hydrazine suspension involving the stages as follows: (a) cooling the inert solvent to a temperature within the range of -68°C to -75°C; and (b) adding hydrazine drop-by-drop to the specified cold inert solvent; and to a method for preparing an immunoconjugate of calicheamicin member and a monoclonal antibody as a carrier involving preparing monoacylated hydrazide.

EFFECT: method eliminates or limits the formation of the undesired bis-hydrazine side products.

31 cl, 15 ex, 9 tbl

FIELD: chemistry.

SUBSTANCE: invention discloses a compound of formula , where: R1 is hydrogen or C1-4alkyl; each of R2 and R4 is independently selected from C1-4alkyl [11C]-C1-4alkyl and [18F]-C1-4fluoroalkyl, provided that at least one of R2 and R4 is [11C]-C1-4alkyl or [18F]-C1-4fluoroalkyl; and R3 is a halogen, used for visualising an NMDA-mediated disease and method of producing said compound.

EFFECT: high accuracy of visualisation.

11 cl, 10 ex, 2 tbl

FIELD: chemistry.

SUBSTANCE: invention discloses organosilicon compounds of general formula Q-[S-G-Si(-O-CX1X2-CX1X3-)3N], where Q denotes SiX43-tX5t-, t equals 0, 1 or 2, Y-C(=O)-Z-C(=O)-, X8-C(=O)-, (X8)HN-C(=O)-, (X8NH-C(=S)-, Y has identical or different values and denotes [-S-G-Si(-O-CX1X2-CX1X3-)3N], G has identical or different values and when Q denotes C6H5-C(=O)-, G denotes a straight or branched, unsubstituted, saturated hydrocarbon chain with two bonds and C3-C30, and for the rest of the values of the substitute, Q denotes a straight or branched, unsubstituted, saturated hydrocarbon chain with two bonds and C1-C30, Z denotes a straight, unsubstituted, saturated hydrocarbon chain with two bonds and C1-C24, X1, X2 and X3 independently denote hydrogen (-H) or C1-C16 alkyl, X4 and X5 independently denote hydrogen (-H), a straight, unsubstituted, saturated hydrocarbon chain with one bond and C1-C24, or Y, X8 in each case has identical or different values and denotes hydrogen (H), a straight, unsubstituted, saturated hydrocarbon chain with one bond and C2-C24 or an unsubstituted aryl group with C6-C24. The invention also discloses versions of methods for synthesis of said compounds. Disclosed organosilicon compounds can be used in rubber mixtures for moulding articles.

EFFECT: when bonded with filler, the disclosed compounds do not release volatile alcohol, and have high reaction capacity with respect to the filler and improved processability.

6 cl, 6 tbl, 21 ex

FIELD: chemistry.

SUBSTANCE: invention relates to methods for synthesis of mercaptoorganyl(alkoxysilanes). Proposed is a method for synthesis of mercaptoorganyl(alkoxysilanes) through hydrogenation bis(alkoxysilyl-organyl)polysulphides in a non-alcohol solvent under the effect of hydrogen and in the presence of a transition metal based catalyst without addition of alcohols, H2S or water. The proposed method can be realised in periodic and in continuous modes and ensures high conversion.

EFFECT: design of a method for synthesis of mercaptoorganyl(alkoxysilanes) through reductive splitting of bis(alkoxysilylorganyl)polysulphides, which avoids additional use of water, alcohols and hydrogen sulphide and ensures high conversion.

13 cl, 5 tbl, 17 ex

FIELD: chemistry.

SUBSTANCE: engineering problem is to design a method for synthesis of mercaptoorganyl(alkoxysilanes) through reductive splitting of bis(alkoxysilylorganyl)polysulphides, which avoids additional use of water, alcohols and hydrogen sulphide and ensures high conversion. Proposed is a method for synthesis of mercaptoorganyl(alkoxysilanes) through hydrogenation of bis(alkoxysilyl-organyl)polysulphides at temperature below 190°C and pressure less than 100 bars under the effect of hydrogen in the presence of a transition metal-based catalyst without addition of water, alcohol or H2S.

EFFECT: proposed method can be realised in periodic and in continuous modes and ensures high conversion.

10 cl, 4 tbl, 13 ex

Up!